Roger M. Perlmutter, M.D., Ph.D., is executive vice president and president of Merck Research Laboratories, Merck’s global R&D organization. Before joining Merck, Dr. Perlmutter was executive vice president and head of R&D at Amgen, from January 2001 to February 2012. During his tenure, he oversaw the development and subsequent approval of a number of novel biologic and small molecule medicines in the areas of cancer, endocrinology, hematology, inflammation and osteoporosis.
Prior to joining Amgen, Dr. Perlmutter worked at Merck Research Laboratories and held roles of increasing responsibility from 1997 to 2001, culminating in his appointment to executive vice president of Worldwide Basic Research and Preclinical Development. He joined Merck as a senior vice president in February 1997. More recently, he served as a director of several biotechnology companies and was a science partner at The Column Group, a biotechnology- focused venture capital firm.
Before assuming leadership roles in industry, Dr. Perlmutter was a professor in the Departments of Immunology, Biochemistry and Medicine at the University of Washington, Seattle, and also served as chairman of its Department of Immunology, where he was a Howard Hughes Medical Institute investigator. His research focused on understanding the signaling pathways that control lymphocyte activation. Prior to his role at the University of Washington, he was a lecturer in the Division of Biology at the California Institute of Technology, Pasadena.
Dr. Perlmutter graduated from Reed College in Portland, Oregon, and received his M.D. and Ph.D. degrees from Washington University in St. Louis, Missouri. He pursued clinical training in internal medicine at Massachusetts General Hospital, Boston, and at the University of California, San Francisco.
Dr. Perlmutter is a Fellow of the American Academy of Arts and Sciences and the American Association for the Advancement of Science.